Is It Too Late To Consider Stryker (SYK) After Recent Valuation Checks?

Simply Wall St.02-01

If you are wondering whether Stryker shares are offering good value right now, it helps to separate the story from the numbers we can actually measure. The stock last closed at US$369.56, with returns...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2608062420?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/94614-main-header/1756253509683","is_english":true,"pubTime":"2026-02-01 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2608062420","market":"sg","top_or_hot":-1,"title":"Is It Too Late To Consider Stryker (SYK) After Recent Valuation Checks?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Stryker shares are offering good value right now, it helps to separate the story from the numbers we can actually measure. The stock last closed at US$369.56, with returns...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-valuatio\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Too Late To Consider Stryker (SYK) After Recent Valuation Checks?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Too Late To Consider Stryker (SYK) After Recent Valuation Checks?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-01 09:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-valuatio><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Stryker shares are offering good value right now, it helps to separate the story from the numbers we can actually measure. The stock last closed at US$369.56, with returns...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-valuatio\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2468319806.SGD","symbol_name":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-valuatio","article_id":"2608062420","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/94614-main-header/1756253509683"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/is-it-too-late-to-consider-stryker-syk-after-recent-valuatio","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2608062420","pubTimestamp":1769908915,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Stryker shares are offering good value right now, it helps to separate the story from the numbers we can actually measure.\nThe stock last closed at US$369.56, with returns of 4.1% over 7 days, 5.1% over 30 days, 6.1% year to date, 34.4% over 3 years and 63.0% over 5 years, while the 1 year return sits at a 4.7% decline.\nRecent headlines around Stryker have kept investor attention on how the company is positioned in the medical technology and healthcare space, and...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","BK4588":"碎股","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","BK4585":"ETF&股票定投概念","GB00B4QBRK32.GBP":"FUNDSMITH EQUITY \"R\" (GBP) INC","LU0882574055.USD":"富达全球健康医疗A ACC","GB00B4LPDJ14.GBP":"FUNDSMITH EQUITY \"R\" (GBP) ACC","LU2404859741.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) INC","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU2404859667.USD":"FUNDSMITH EQUITY FUND \"R\" (USD) ACC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4082":"医疗保健设备","SYK":"史赛克","LU0690374961.EUR":"FUNDSMITH EQUITY \"R\" (EUR) INC","LU0058720904.USD":"联博国际健康护理基金A","BK4504":"桥水持仓","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0690374615.EUR":"FUNDSMITH EQUITY \"R\" (EUR) ACC"},"translate_title":"在最近的估值检查之后，考虑史赛克（SYK）是否为时已晚？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"SYK":1.5},"content_text":"If you are wondering whether Stryker shares are offering good value right now, it helps to separate the story from the numbers we can actually measure. The stock last closed at US$369.56, with returns of 4.1% over 7 days, 5.1% over 30 days, 6.1% year to date, 34.4% over 3 years and 63.0% over 5 years, while the 1 year return sits at a 4.7% decline. Recent headlines around Stryker have kept investor attention on how the company is positioned in the medical technology and healthcare space, and what that might mean for its longer term prospects. These updates help frame whether the recent share price moves reflect changing expectations or simply short term sentiment shifts. Despite this backdrop, Stryker currently holds a valuation score of 0/6. This means it is assessed as undervalued in none of the six basic checks we will walk through next. We will also look at a more complete way to think about valuation by the end of the article.  Stryker scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Stryker Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those cash flows back to today, aiming to arrive at an implied value per share. For Stryker, the model used here is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections. The latest twelve month free cash flow is about $4.27b. Analyst inputs and extrapolated estimates point to projected free cash flow of around $6.01b in 2028, with a full set of ten year projections stepping up from $4.40b in 2026 to about $8.55b in 2035, all in $ terms. When those projected cash flows are discounted, the model suggests an estimated intrinsic value of roughly $349.37 per share. Compared with the recent share price of $369.56, this implies the stock is about 5.8% overvalued, which is a relatively small gap and could easily sit within a normal margin of error for this kind of model. Result: ABOUT RIGHT Stryker is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act. SYK Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Stryker. Approach 2: Stryker Price vs Earnings For profitable companies like Stryker, the P/E ratio is a straightforward way to link what you pay for each share to the earnings that support that price. Investors usually look for a P/E level that lines up with their expectations for future growth and the risk they see in those earnings, so higher growth and lower perceived risk often go together with a higher “normal” P/E, and the reverse is also true. Stryker currently trades on a P/E of 43.54x. That sits above the Medical Equipment industry average of 31.08x and slightly above the peer average of 42.28x. Simply Wall St’s Fair Ratio for Stryker is 40.15x, which is its proprietary estimate of what the P/E “should” be given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This Fair Ratio can be more useful than a simple comparison with peers or the wider industry, because it adjusts for Stryker’s own characteristics rather than assuming all companies deserve the same multiple. Compared with that Fair Ratio of 40.15x, Stryker’s current P/E of 43.54x points to the shares trading at a premium, suggesting they are overvalued on this metric. Result: OVERVALUED NYSE:SYK P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Discover 1420 companies where insiders are betting big on explosive growth. Upgrade Your Decision Making: Choose your Stryker Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which simply means writing the story you believe about a company and tying that story to your own numbers for fair value, future revenue, earnings and margins. A Narrative connects three things in a straight line: what you think is happening with the business, how that view translates into a financial forecast and the fair value that drops out of those forecasts. On Simply Wall St, Narratives sit in the Community page and are used by millions of investors. This allows you to quickly see different fair values for Stryker and compare them with today’s share price to help decide whether you see it as closer to a buy, a hold or a sell for your own situation. Because Narratives update automatically when new information like earnings releases or news headlines arrives, you are not locked into a static view. You can always see how your fair value for Stryker shifts compared with someone who has set a much higher or much lower value using different assumptions. Do you think there's more to the story for Stryker? Head over to our Community to see what others are saying! NYSE:SYK 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2608062420","isCrawlerRequest":true}